2020 Master Class in Lung Transplantation


←  BACK TO 2020 ISHLT ACADEMIES
 

When & Where

Tuesday, April 21, 2020
Morning Course: 8:00 AM - 1:00 PM
Afternoon Course: 2:00 PM - 7:00 PM

515ABC
Montréal, Canada
 

Chair

Daniel F. Dilling, MD
Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA

Co-Chair

Miranda Paraskeva, MBBS
Alfred Hospital, Melbourne, Australia


 

Case Moderators

Marcelo Cypel, MD, Toronto General Hospital, Toronto, Canada
Michelle Murray, MD, MSc, MRCPI, Mater Misericordiae University Hospital, Dublin, Ireland
Aleem Siddique, MBBS, University of Nebraska Medical Center, Omaha, NE, USA
Amparo Sole, MD, PhD, Hospital Universitario la Fe Unidad de Transplante Pulmonar, Valencia, Spain

Case Discussants

Maria Crespo, MD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Shahid Husain, MD, MS, Toronto General Hospital, Toronto, Canada
Jonathan Singer, MD, University of California San Francisco, San Francisco, CA, USA
Dirk Van Raemdonck, MD, University of Leuven, Leuven, Belgium
The educational goals of this activity are to provide those who care for candidates and recipients of lung transplant recognize all-too-well that there are many nuanced situations that challenge even the most seasoned physician, surgeon, nurse, or pharmacist. In this Master Class, we will dive deeply into 4 of the most pressing and dynamic topics in lung transplantation, bringing expertise and opinion from some of the thought leaders in our field. We will tackle problems involving patients with complex infection, frailty phenotype, airway complications, and the use of ex-vivo lung perfusion.
The course is directed toward experienced clinicians who seek to refine their knowledge in these areas and will invite open discussion and debate.
After completion of this Class, participants will have improved competence and professional performance in their ability to:
 
  1. Know the common treatment strategies used for certain complex infections and discuss the implicationson their control in the context of peri-operative and post-operative immunosuppression
  2. Understand the 2018 ISHLT grading system for airway complications, including its rationale, whilerecognizing practices aimed at their prevention as well as therapeutic options for their management.
  3. Know the tools that can be used to assess or measure frailty and discuss how they might be applied to acandidate for a lung transplant.
  4. Understand best practice for developing, utilizing, and maintaining a successful EVLP program with focuson knowing which donor lungs should undergo EVLP and management strategies of donor lung duringEVLP
Physicians
Accreditation Statement – The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement – ISHLT designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and ISHLT. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 4.25 contact hours for nurses and 2.25 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.
Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. Please refer to the Participant Notification document for a list of all disclosures. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.